Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:40 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC)
NCT05770882 · Great Novel Therapeutics Biotech & Medicals Corporation · PHASE1/PHASE2 · terminated · last registry update 2025-03-11 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The overall profile does not support development for Hepatocellular Carcinoma” | – | Registry record, Great Novel Therapeutics Biotech & Medicals Corporation |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ABL1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-03-11Also stopped (withdrawn): M.D. Anderson Cancer Center, Regorafenib + Lorigerlimab (NCT07137390)
- 2026-03-09Also stopped (terminated): Translational Research in Oncology, Regorafenib in combination with pembrolizumab (NCT04777851)
- 2026-03-05Results posted on the registry: Wake Forest University Health Sciences, Regorafenib (NCT04327700)
- 2026-03-05Also stopped (terminated): Wake Forest University Health Sciences, Regorafenib (NCT04327700)
- 2026-03-02Also stopped (terminated): M.D. Anderson Cancer Center, Asciminib (NCT04216563)
- 2026-02-27Results posted on the registry: Massachusetts General Hospital, Umbralisib + Rituximab (NCT03919175)
- 2026-02-27Also stopped (terminated): Massachusetts General Hospital, Umbralisib + Rituximab (NCT03919175)
- 2026-02-25Also stopped (withdrawn): M.D. Anderson Cancer Center, Regorafenib + Lorigerlimab (NCT07223567)
- 2026-02-06Phase 3 first posted: Nanjing Sanhome Pharmaceutical, Co., Ltd., SH006 + Bevacizumab (NCT07392866)
- 2026-02-03Phase 3 first posted: Shanghai JMT-Bio Inc., JSKN003 + Physician choiced treatment, include: TAS-102, Regorafenib, Fruquintinib. (NCT07384377)
- 2026-01-30Phase 3 first posted: Ningbo Newbay Technology Development Co., Ltd, NB003 + regorafenib (NCT07379047)
- 2026-01-29Results posted on the registry: Indiana University, Imatinib Mesylate (NCT03997903)
- 2026-01-29Also stopped (terminated): Indiana University, Imatinib Mesylate (NCT03997903)
- 2026-01-20Results posted on the registry: Novartis Pharmaceuticals, Nilotinib (NCT00756509)
- 2026-01-20Results posted on the registry: Bristol-Myers Squibb, BMS-986288 + Nivolumab (NCT03994601)
- 2026-01-20Also stopped (terminated): Anwaar Saeed, Regorafenib + Pembrolizumab (NCT06006923)
- 2026-01-15Results posted on the registry: M.D. Anderson Cancer Center, Dasatinib (NCT00254423)
- 2026-01-09Results posted on the registry: M.D. Anderson Cancer Center, Asciminib (NCT04216563)
- 2026-01-06Also stopped (terminated): H. Lee Moffitt Cancer Center and Research Institute, Umbralisib (NCT04163718)
- 2025-12-23Phase 3 first posted: Xi'an Xintong Pharmaceutical Research Co.,Ltd., Pracytarabine + regorafenib (NCT07300488)
- 2025-12-18Results posted on the registry: SWOG Cancer Research Network, Bosutinib + Dasatinib (NCT03654768)
- 2025-12-08Also stopped (terminated): M.D. Anderson Cancer Center, Ponatinib (NCT01570868)
- 2025-12-03Results posted on the registry: Bristol-Myers Squibb, Nivolumab + Trametinib (NCT03377361)
- 2025-10-21Phase 3 first posted: GlaxoSmithKline, IDRX-42 + Sunitinib (NCT07218926)
- 2025-10-03Also stopped (terminated): National Cancer Institute (NCI), Dasatinib (NCT05198843)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision